Index RUT P/E - EPS (ttm) -1.12 Insider Own 14.70% Shs Outstand 411.94M Perf Week -6.82%
Market Cap 1.52B Forward P/E - EPS next Y -0.22 Insider Trans 0.00% Shs Float 351.42M Perf Month 29.47%
Enterprise Value 1.27B PEG - EPS next Q -0.14 Inst Own 57.14% Short Float 37.26% Perf Quarter 46.43%
Income -390.98M P/S 5.77 EPS this Y 54.00% Inst Trans 15.21% Short Ratio 8.70 Perf Half Y 67.73%
Sales 263.44M P/B 2.18 EPS next Y 55.72% ROA -42.88% Short Interest 130.93M Perf YTD 35.16%
Book/sh 1.70 P/C 5.12 EPS next 5Y - ROE -55.50% 52W High 5.63 -34.46% Perf Year 4.24%
Cash/sh 0.72 P/FCF - EPS past 3/5Y 23.93% 10.23% ROIC -52.62% 52W Low 1.64 125.21% Perf 3Y -41.71%
Dividend Est. - EV/EBITDA - Sales past 3/5Y - - Gross Margin 17.09% Volatility 7.60% 10.87% Perf 5Y -88.23%
Dividend TTM - EV/Sales 4.83 EPS Y/Y TTM 13.67% Oper. Margin -151.18% ATR (14) 0.38 Perf 10Y -26.20%
Dividend Ex-Date - Quick Ratio 2.83 Sales Y/Y TTM 60.57% Profit Margin -148.41% RSI (14) 48.10 Recom 1.64
Dividend Gr. 3/5Y - - Current Ratio 3.20 EPS Q/Q 31.43% SMA20 -10.43% Beta 0.72 Target Price 9.00
Payout - Debt/Eq 0.07 Sales Q/Q 17.66% SMA50 15.47% Rel Volume 1.56 Prev Close 3.87
Employees 975 LT Debt/Eq 0.06 Earnings Feb 24 BMO SMA200 46.12% Avg Volume 15.04M Price 3.69
IPO Sep 01, 2009 Option/Short Yes / Yes EPS/Sales Surpr. -2.92% 7.44% Trades
Volume 23,453,378 Change -4.65%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-25-26 Upgrade Citizens
Mkt Perform → Mkt Outperform
$5
Jul-15-25 Downgrade Goldman
Neutral → Sell
$1
May-16-25 Downgrade UBS
Buy → Neutral
$2
May-12-25 Downgrade Truist
Buy → Hold
May-09-25 Downgrade Citizens JMP
Mkt Outperform → Mkt Perform
Oct-24-24 Initiated UBS
Buy
$17
Jul-29-24 Downgrade Piper Sandler
Overweight → Neutral
$19 → $10
Nov-20-23 Initiated Goldman
Buy
$12
Sep-18-23 Reiterated Barclays
Overweight
$40 → $18
May-30-23 Upgrade Wells Fargo
Equal Weight → Overweight
$11 → $17
Mar-27-23 Resumed Wells Fargo
Equal Weight
$11
Jan-27-23 Upgrade Piper Sandler
Neutral → Overweight
$11 → $14
Dec-09-22 Downgrade Goldman
Buy → Neutral
$20 → $6
Oct-31-22 Initiated Guggenheim
Neutral
Aug-18-22 Resumed Wells Fargo
Equal Weight
$14
Jan-28-22 Upgrade Stifel
Hold → Buy
$23 → $25
Dec-07-21 Resumed Cowen
Outperform
Jun-10-21 Upgrade JMP Securities
Mkt Perform → Mkt Outperform
$32
May-20-21 Downgrade Piper Sandler
Overweight → Neutral
$35 → $18
May-19-21 Downgrade Stifel
Buy → Hold
Show Previous Ratings
Mar-20-26 05:15PM
Mar-07-26 08:10PM
01:28AM
Mar-06-26 01:06PM
12:01PM
09:00AM
Loading…
Mar-05-26 09:00AM
Feb-26-26 02:27PM
09:40AM
08:00AM
Feb-25-26 01:33PM
11:01AM
Feb-24-26 04:32PM
04:01PM
02:14PM
12:49PM
09:40AM
Loading…
09:40AM
09:02AM
07:26AM
(Associated Press Finance)
07:00AM
07:00AM
Feb-23-26 09:58AM
Feb-20-26 05:15PM
Feb-19-26 09:58AM
Feb-17-26 08:41PM
Feb-11-26 06:39PM
04:05PM
Feb-06-26 11:02AM
Feb-05-26 05:15PM
Jan-16-26 05:15PM
Jan-15-26 02:33PM
11:13AM
Loading…
Dec-31-25 11:13AM
Dec-29-25 09:50AM
Dec-19-25 05:15PM
Dec-07-25 09:45AM
Nov-21-25 05:15PM
Nov-11-25 06:45AM
Nov-07-25 01:45PM
08:45AM
Nov-06-25 09:15AM
08:19AM
(Associated Press Finance)
08:00AM
Nov-05-25 05:20PM
Nov-04-25 06:00PM
Nov-03-25 10:00AM
07:00AM
Oct-23-25 04:05PM
Oct-17-25 05:15PM
06:17AM
Oct-15-25 08:45AM
Oct-13-25 05:53AM
Sep-20-25 02:43AM
Sep-19-25 05:00PM
10:05AM
Sep-17-25 08:30AM
Sep-08-25 12:30AM
Aug-29-25 08:30AM
Aug-27-25 04:28PM
Aug-26-25 09:17AM
Aug-25-25 05:15PM
10:30AM
(Associated Press Finance)
08:48AM
Aug-24-25 09:30AM
Aug-22-25 11:45PM
(Insider Monkey) +5.91%
-5.95%
05:15PM
Aug-19-25 03:16PM
Aug-18-25 04:15PM
Aug-17-25 11:41PM
Aug-14-25 12:22PM
Aug-13-25 10:30AM
(Associated Press Finance) +9.87%
Aug-12-25 05:31PM
Aug-09-25 04:21AM
Aug-08-25 07:31PM
(Motley Fool) -20.08%
-6.64%
12:47PM
Aug-07-25 05:10PM
04:20PM
(Associated Press Finance)
04:01PM
06:02AM
Aug-06-25 06:10PM
Aug-05-25 06:05PM
Aug-01-25 06:46AM
Jul-30-25 04:46AM
Jul-29-25 03:29AM
Jul-24-25 04:05PM
10:30AM
(Associated Press Finance)
Jul-23-25 10:30AM
(Associated Press Finance) +26.84%
Jul-21-25 08:30AM
Jul-18-25 05:15PM
Jul-15-25 07:30AM
Jul-14-25 07:30AM
Jul-10-25 04:01PM
Jul-06-25 06:47AM
Jun-29-25 08:36AM
Jun-27-25 06:57PM
12:00PM
Jun-24-25 01:36PM
09:00AM
Jun-23-25 04:05PM
Jun-20-25 11:56AM
11:56AM
Jun-19-25 01:03PM
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Vogt Frederick G Interim CEO & General Counsel Mar 05 '26 Option Exercise 0.00 62,493 0 556,293 Mar 06 05:02 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Mar 05 '26 Option Exercise 0.00 31,246 0 148,477 Mar 06 05:01 PM Puri Raj K. Chief Regulatory Officer Mar 05 '26 Option Exercise 0.00 39,059 0 257,590 Mar 06 05:00 PM BILINSKY IGOR Chief Operating Officer Mar 05 '26 Option Exercise 0.00 31,246 0 142,394 Mar 06 05:00 PM Vogt Frederick G Interim CEO & General Counsel Mar 02 '26 Option Exercise 0.00 52,087 0 516,609 Mar 04 05:01 PM BILINSKY IGOR Chief Operating Officer Mar 02 '26 Option Exercise 0.00 12,307 0 118,051 Mar 04 05:01 PM Puri Raj K. Chief Regulatory Officer Mar 02 '26 Option Exercise 0.00 5,470 0 221,329 Mar 04 05:00 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Mar 02 '26 Option Exercise 0.00 12,697 0 124,353 Mar 04 05:00 PM Kirby Daniel Gordon Chief Commercial Officer Feb 24 '26 Option Exercise 0.00 120,000 0 173,546 Feb 26 05:00 PM Kirby Daniel Gordon Chief Commercial Officer Feb 10 '26 Option Exercise 0.00 39,996 0 69,996 Feb 12 05:00 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Dec 02 '25 Option Exercise 0.00 3,906 0 113,640 Dec 03 05:04 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Dec 01 '25 Option Exercise 0.00 8,789 0 114,198 Dec 03 05:04 PM BILINSKY IGOR Chief Operating Officer Dec 02 '25 Option Exercise 0.00 3,516 0 107,530 Dec 03 05:02 PM BILINSKY IGOR Chief Operating Officer Dec 01 '25 Option Exercise 0.00 8,789 0 108,478 Dec 03 05:02 PM Vogt Frederick G Interim CEO & General Counsel Dec 02 '25 Option Exercise 0.00 10,417 0 468,948 Dec 03 05:01 PM Vogt Frederick G Interim CEO & General Counsel Dec 01 '25 Option Exercise 0.00 41,669 0 476,232 Dec 03 05:01 PM Puri Raj K. Chief Regulatory Officer Dec 01 '25 Option Exercise 0.00 5,469 0 218,326 Dec 03 05:00 PM Vogt Frederick G Interim CEO & General Counsel Sep 02 '25 Option Exercise 0.00 52,086 0 456,690 Sep 04 06:35 PM Puri Raj K. Chief Regulatory Officer Sep 02 '25 Option Exercise 0.00 5,470 0 215,324 Sep 04 06:30 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Sep 02 '25 Option Exercise 0.00 12,697 0 111,857 Sep 04 06:30 PM BILINSKY IGOR Chief Operating Officer Sep 02 '25 Option Exercise 0.00 12,306 0 105,939 Sep 04 06:30 PM Kirby Daniel Gordon Chief Commercial Officer Jun 05 '25 Buy 1.84 30,000 55,200 30,000 Jun 06 04:05 PM Puri Raj K. Chief Regulatory Officer Jun 02 '25 Option Exercise 0.00 5,469 0 212,321 Jun 04 04:51 PM Vogt Frederick G Interim CEO & General Counsel Jun 02 '25 Option Exercise 0.00 52,085 0 426,731 Jun 04 04:50 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jun 02 '25 Option Exercise 0.00 12,695 0 105,608 Jun 04 04:49 PM BILINSKY IGOR Chief Operating Officer Jun 02 '25 Option Exercise 0.00 12,305 0 99,883 Jun 04 04:47 PM Bellemin Jean-Marc Chief Financial Officer Jun 02 '25 Option Exercise 0.00 8,789 0 64,993 Jun 04 04:46 PM Puri Raj K. Chief Regulatory Officer May 23 '25 Buy 1.74 5,600 9,743 206,852 May 27 04:06 PM Vogt Frederick G Interim CEO & General Counsel May 14 '25 Buy 1.69 25,000 42,250 374,646 May 16 04:05 PM
